SCHEMBL4124535

SCHEMBL4124535

COC(=O)CCOC1CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.41
EPHX2 P34913 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
EPHX1 P07099 1/20 0.34
GNAI3 P08754 2/20 0.34
GNAO1 P09471 2/20 0.34
GNAI1 P63096 2/20 0.34
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 2/20 0.32
CA12 O43570 1/20 0.32
CA14 Q9ULX7 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8552789 0.98 TSHR (0.40) TSHREPHX2SMN1; SMN2EPHX1GNAI3
SCHEMBL24476659 0.87 TSHR (0.42) TSHREPHX2GNAI3GNAO1GNAI1
SCHEMBL25468869 0.87 TSHR (0.50) TSHREPHX2SMN1; SMN2KMT2AALDH1A1
Hydrochloric Acid SCHEMBL28649285 0.85 GNAI3 (0.42) TSHREPHX2GNAI3GNAO1GNAI1
SCHEMBL1998489 0.81 EPHX1 (0.36) TSHREPHX2SMN1; SMN2EPHX1GNAI3
SCHEMBL27358924 0.81 EPHX2 (0.32) EPHX2
Hydrochloric Acid SCHEMBL8383740 0.80 EPHX1 (0.35) TSHREPHX2SMN1; SMN2EPHX1GNAI3
SCHEMBL14640812 0.79 GABRA5 (0.40) TSHREPHX1GABRPGABRDGABRA1
SCHEMBL29165797 0.79 TSHR (0.44) TSHREPHX2SMN1; SMN2EPHX1GNAI3
Hydrochloric Acid SCHEMBL31463606 0.78 GABRA5 (0.39) TSHREPHX1GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072686-A1 KRAS G12D MUTATION TARGETING COMPOUNDS SUMMIT THERAPEUTICS INC. (US) 2025-04-03 WO disclosed
WO-2024137358-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2024-06-27 WO disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR TSHR 1672/4885EPHX2 801/4885SMN1; SMN2 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.